- Big Health Care Disparities Persist Across the U.S., New Report Finds
- Teens Often Bullied Online About Their Weight: Study
- Work That Challenges Your Brain Helps You Stay Sharp With Age
- Urine Test Might Spot Head-and-Neck Cancers Early
- Many Seniors Are Overmedicated, But ChatGPT Might Prevent That
- Antipsychotics May Do Great Harm to People With Dementia: Report
- Two-Drug Combo Curbs Drinking for People Battling Severe Alcoholism
- Most Homeless Americans Are Battling Mental Illness
- FDA Recalls Heart Failure Devices Linked to Injuries and Deaths
- COVID Does Not Spur Asthma in Kids, Study Finds
Aptiom Approved to Treat Seizures
MONDAY, Nov. 11Aptiom (eslicarbazepine acetate) has been approved by the U.S. Food and Drug Administration as an add-on drug to help treat adults with partial epileptic seizures.
Epilepsy, caused by abnormal activity in the brain’s nerve cells, is diagnosed in some 200,000 people annually in the United States, the agency said in a news release. So-called “partial” seizures are the most common type of seizure among people with epilepsy, triggering possible symptoms including repetitive movement of limbs, unusual behavior and convulsions.
Aptiom’s safety and effectiveness were evaluated in three clinical studies. The most common side effects noted were dizziness, drowsiness, nausea, headache, double vision and loss of coordination.
As with other anti-epileptic drugs, Aptiom may trigger thoughts of suicide in a small number of users, the FDA said. People who take the drug should contact a doctor immediately if they have thoughts of suicide, or worsening anxiety or depression, the agency warned.
Aptiom is marketed by Sunovion Pharmaceuticals, based in Marlborough, Mass.
More information
To learn more about epilepsy, visit the U.S. Centers for Disease Control and Prevention.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.